JPRN-UMIN000001323已完成未知
Open-label cross-over study to evaluate the amount of residual inhaled corticosteroid (hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP) and fluticasone propionate dry powder inhaler (FP-DPI)) in the mouths of elderly asthmatic patients after each inhalation - The evaluation of the amount of residual inhaled corticosteroid (HFA-BDP and FP-DPI) in the mouths of elderly asthmatic patients after each inhalation.
JA Gifu Kouseiren Tohno-Kousei Hospital0 个研究点目标入组 22 人开始时间: 2008年8月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 65years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)any hypersensitivity history for steroids, 2)under treatment with oral steroids, 3)under desensitization or non-specific therapy which is newly initiated within 6 months before this study, 4)other coexisting chronic respiratory diseases except for chronic obstructive pulmonary disease (COPD), 5)severe hepatic or renal disease, heart failure, hematologic diseases, or other severe co-morbid disease, 6)under treatment for chronic respiratory infectious diseases, 7)expectation of poor drug compliance, 8)Inappropriate patients from the doctor's viewpoint
研究者
相似试验
已完成
不适用
An open label, crossover study to investigate the safety and tolerability of Sifrol® (pramipexole) (Boehringer Ingelheim) prolonged release tablets in order to establish the maximum tolerable dose and to assess bioequivalence of Pramipexole prolonged release tablets (Synthon B.V.) compared to Sifrol® prolonged release tablets (Boehringer Ingelheim) in healthy subjects in steady-state conditions10042258parkinson's diseaseNL-OMON36833Synthon B.V52
已完成
不适用
A study of two different formulations of buprenorphine in healthy volunteers.PainAddictionACTRN12617000002381iX Biopharma Pty Ltd14
招募中
不适用
Vitamin D3 clinicaltrial I in healthy adult volunteersKCT0000411Dream Pharma36
招募中
不适用
Ibandronate clinicaltrial Phase I in healthy adult volunteersKCT0000191Dream Pharma84
已完成
3 期
An open-label randomised cross-over study to evaluate the albuminuria lowering effect of dapagliflozin, exenatide and their combination in patients with type 2 diabetes10012653Diabetes MellitusdiabetesNL-OMON46820Martini Ziekenhuis20